Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_FITC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
  • GK1.5_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100405 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100406 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  4. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  5. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  6. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  7. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  8. Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
  9. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  10. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  11. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  12. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  13. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  14. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  15. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  16. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  17. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  18. Balood M, et al. 2022. Nature. 611:405. PubMed
  19. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  20. Zhang Z, et al. 2022. Integr Cancer Ther. 21:15347354221138534. PubMed
  21. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  22. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  23. Chen C, et al. 2022. J Neuroinflammation. 19:315. PubMed
  24. Qin S, et al. 2023. Acta Pharm Sin B. :. PubMed
  25. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  26. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  27. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  28. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  29. Sylvester MA, et al. 2022. Am J Physiol Renal Physiol. 322:F245. PubMed
  30. Zander R, et al. 2022. Immunity. 55:475. PubMed
  31. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  32. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  33. Qiu Z, et al. 2022. J Exp Med. 219:. PubMed
  34. Lin J, et al. 2022. Adv Sci (Weinh). 9:e2202633. PubMed
  35. Hamdi L, et al. 2022. Ann Clin Transl Neurol. 9:1792. PubMed
  36. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  37. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  38. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  39. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  40. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  41. Mackin S, et al. 2023. Nat Microbiol. 8:569. PubMed
  42. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  43. Liu H, et al. 2023. Breast Cancer Res. 25:43. PubMed
  44. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  45. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  46. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  47. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  48. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  49. Peymanfar Y, et al. 2023. Int J Mol Sci. 24:. PubMed
  50. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  51. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  52. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  53. Solvay M, et al. 2023. J Immunother Cancer. 11:. PubMed
  54. Wang Z, et al. 2023. Sci Adv. 9:eabo4100. PubMed
  55. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  56. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  57. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  58. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  59. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  60. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  61. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  62. He R, et al. 2021. J Immunol. 206:2353. PubMed
  63. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  64. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  65. Sega E, et al. 2008. Int J Radiat Oncol Biol Phys. 71:559. PubMed
  66. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  67. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  68. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  69. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  70. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  71. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  72. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  73. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  74. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  75. Toomer G, et al. 2022. Viruses. 14:. PubMed
  76. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  77. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  78. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  79. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  80. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  81. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  82. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  83. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  84. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  85. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  86. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  87. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  88. Guan H, et al. 2012. PLoS One. 7:e35650. PubMed
  89. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  90. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  91. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  92. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  93. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  94. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  95. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
  96. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  97. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  98. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  99. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  100. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  101. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  102. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  103. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  104. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  105. White C, et al. 2014. J Immunol. 193:5933. PubMed
  106. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  107. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  108. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  109. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  110. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  111. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  112. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  113. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  114. Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed
  115. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  116. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  117. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  118. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  119. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  120. Wang Z, et al. 2020. J Clin Invest. 130:3717. PubMed
  121. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  122. Raineri D, et al. 2021. Biomedicines. 10:. PubMed
  123. He X, et al. 2021. Small. 17:e2007165. PubMed
  124. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  125. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  126. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  127. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  128. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  129. Deng Z, et al. 2020. World J Gastrointest Oncol. 1091:12. PubMed
  130. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  131. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  132. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  133. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  134. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  135. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  136. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  137. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  138. Ahmari N, et al. 2016. Physiol Genomics. 48: 526 - 536. PubMed
  139. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  140. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  141. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  142. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  143. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  144. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  145. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  146. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  147. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  148. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  149. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  150. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  151. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  152. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  153. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  154. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  155. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  156. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  157. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  158. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  159. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  160. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  161. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  162. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  163. Mencl S, et al. 2014. J Neuroimmunol. 274:125. PubMed
  164. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  165. Sun H, et al. 2022. Front Immunol. 13:818017. PubMed
  166. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  167. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  168. Lang V, et al. 2021. Elife. 10:. PubMed
  169. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  170. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  171. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  172. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  173. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  174. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  175. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  176. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  177. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  178. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  179. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  180. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  181. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  182. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  183. Ma K, et al. 2022. iScience. 25:104347. PubMed
  184. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  185. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  186. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  187. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  188. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  189. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  190. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  191. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  192. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  193. Reynolds CJ, et al. 2018. Sci Rep. 8:672. PubMed
  194. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  195. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  196. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  197. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  198. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  199. Li J, et al. 2020. Development. :. PubMed
  200. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  201. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  202. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  203. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  204. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  205. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  206. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  207. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  208. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  209. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  210. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  211. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  212. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  213. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  214. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  215. Khosravi N, et al. 2018. Cancer Immunol Res. 0.797222222. PubMed
  216. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  217. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  218. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  219. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  220. Pan L, et al. 2022. Front Immunol. 13:837497. PubMed
  221. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  222. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  223. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  224. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  225. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  226. Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed
  227. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  228. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  229. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  230. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  231. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  232. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  233. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  234. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  235. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  236. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  237. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  238. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  239. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  240. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  241. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  242. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  243. Blaszczak AM, et al. 2019. J Immunol. 202:2451. PubMed
  244. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  245. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  246. Wang Y, et al. 2022. Nat Commun. 13:1454. PubMed
  247. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  248. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  249. Li Z, et al. 2022. Evid Based Complement Alternat Med. 2022:7421265. PubMed
  250. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  251. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  252. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  253. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  254. Zeng A, et al. 2020. Oncol Rep. . PubMed
  255. Bartley A, et al. 2018. Front Physiol. 9:1593. PubMed
  256. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  257. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  258. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  259. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  260. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  261. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  262. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
  263. Gawish R, et al. 2022. Elife. 11:. PubMed
  264. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  265. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  266. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  267. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  268. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  269. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  270. Lestari SR, et al. 2020. J Ayurveda Integr Med. 11:414. PubMed
  271. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  272. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  273. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
RRID
AB_312690 (BioLegend Cat. No. 100405)
AB_312690 (BioLegend Cat. No. 100406)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account